RecruitingPhase 2NCT05873192
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Sponsor: M.D. Anderson Cancer Center
Houston, TX
Ensayos clínicos de cáncer de próstata
345 estudios buscan participantes en EE. UU.
La mayoría de los ensayos de cáncer de próstata son de fase 2 e incluyen combinaciones de terapia hormonal, tratamientos dirigidos con radioligandos e investigación con imágenes. La elegibilidad suele depender del nivel de PSA, de si el cáncer se ha extendido y de si todavía responde a la terapia hormonal. Para personas con enfermedad en etapa temprana hay estudios de vigilancia activa y de sobrevivientes.
Mostrando 40 de 345 estudios (en inglés)
RecruitingPhase not listedNCT00034216
Collection of Blood From Patients With Cancer
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase not listedNCT00451022
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase not listedNCT01834001
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase not listedNCT02594202
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase not listedNCT04706663
Precision-Based Genomics in Prostate Cancer
Sponsor: National Cancer Institute (NCI)
La Jolla, CA · San Francisco, CA · Evanston, IL · +8 more sites
RecruitingPhase not listedNCT04775355
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
Sponsor: City of Hope Medical Center
Duarte, CA
RecruitingPhase 2NCT06096870
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase 2NCT06161506
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Duarte, CA · La Jolla, CA · Los Angeles, CA · +20 more sites
RecruitingPhase 1NCT06879041
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: AstraZeneca
Palo Alto, CA · San Diego, CA · Miami, FL · +9 more sites
RecruitingPhase 3NCT07365995
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Sponsor: BioNTech SE
Santa Barbara, CA · Aurora, CO · Fort Myers, FL · +18 more sites
RecruitingPhase 1 / Phase 2NCT07667400
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Bethesda, MD
RecruitingPhase 1NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Sponsor: Pfizer
Tucson, AZ · +42 more sites
RecruitingNot applicableNCT07221825
Low-Count Quantitative SPECT for Men Treated With Radium-223
Sponsor: Washington University School of Medicine
St Louis, MO
RecruitingPhase 1 / Phase 2NCT07226986
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Sponsor: Novartis Pharmaceuticals
Los Angeles, CA · Durham, NC · El Paso, TX · +1 more sites
RecruitingNot applicableNCT07526545
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
Sponsor: University of Michigan Rogel Cancer Center
Ann Arbor, MI
RecruitingPhase not listedNCT07677267
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Sponsor: Novartis Pharmaceuticals
East Hanover, NJ
RecruitingPhase 1NCT07824349
JUR-003 in Adult Patients With Metastatic Prostate Cancer
Sponsor: Juri Biosciences, Inc.
Grand Rapids, MI · Lake Success, NY · Nashville, TN · +1 more sites
RecruitingPhase not listedNCT07875192
Hugo™ Robotic Assisted Surgery (RAS) System in Prostatectomy Patients Treated in an ASC Setting
Sponsor: Central Ohio Urology Group
Columbus, OH
RecruitingPhase 2NCT05691465
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Sponsor: National Cancer Institute (NCI)
Duarte, CA · Los Angeles, CA · +10 more sites
RecruitingNot applicableNCT06325046
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Sponsor: Mayo Clinic
Albert Lea, MN · Mankato, MN · Rochester, MN · +2 more sites
RecruitingPhase 3NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Sponsor: Pfizer
Chandler, AZ · Gilbert, AZ · Glendale, AZ · +36 more sites
RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Huntsville, AL · Chandler, AZ · +124 more sites
RecruitingPhase 1 / Phase 2NCT07590934
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Sponsor: AstraZeneca
Duarte, CA · Encino, CA · South Pasadena, CA · +9 more sites
RecruitingEarly Phase 1NCT05045066
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
Sponsor: Mayo Clinic
Scottsdale, AZ · Jacksonville, FL
RecruitingEarly Phase 1NCT05851365
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
Sponsor: Robert Flavell, MD, PhD
San Francisco, CA
RecruitingPhase 2NCT06049355
EMBRACE: Exercising Together
Sponsor: OHSU Knight Cancer Institute
Portland, OR
RecruitingNot applicableNCT06511141
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Sponsor: Axonics, Inc.
Birmingham, AL · Fairhope, AL · Scottsdale, AZ · +20 more sites
RecruitingPhase 1 / Phase 2NCT07871435
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
Sponsor: GI Innovation, Inc.
New York, NY
RecruitingPhase 1 / Phase 2NCT07529717
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Sponsor: AstraZeneca
Orlando, FL · East Brunswick, NJ · Hackensack, NJ · +1 more sites
RecruitingPhase not listedNCT07690917
A Study of a New PET Scanner in People With Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Basking Ridge, NJ · Middletown, NJ · Montvale, NJ · +4 more sites
RecruitingPhase 2NCT07287150
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Hoffmann-La Roche
Los Angeles, CA · San Francisco, CA · Iowa City, IA · +3 more sites
RecruitingPhase 2NCT07745361
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Sponsor: Monte Rosa Therapeutics, Inc
Los Angeles, CA · Newport Beach, CA · Colorado Springs, CO · +11 more sites
RecruitingPhase not listedNCT05497024
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Sponsor: Parabilis Medicines, Inc.
Phoenix, AZ · Scottsdale, AZ · Tucson, AZ · +28 more sites
RecruitingPhase 1NCT05997615
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Sponsor: Astellas Pharma Global Development, Inc.
Duarte, CA · Irvine, CA · Orange, CA · +5 more sites
RecruitingPhase 1NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Sponsor: Eli Lilly and Company
Duarte, CA · Santa Monica, CA · Stanford, CA · +13 more sites
RecruitingPhase 4NCT07569926
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Sponsor: Blue Earth Diagnostics
San Diego, CA · Atlanta, GA · Boston, MA · +3 more sites
RecruitingPhase 1NCT05800665
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Sponsor: Genentech, Inc.
Scottsdale, AZ · New Haven, CT · Orlando, FL · +2 more sites
La información proviene de ClinicalTrials.gov y es solo informativa; no es consejo médico. Confirme siempre su elegibilidad con el equipo del estudio y hable con su médico antes de tomar decisiones sobre su atención.